Accelerating enrollment with high-risk patient populations in pulmonary trials
From asthma to COPD, recruitment for patients facing pulmonary illness requires attention to detail and a high level of care.
1nHealth takes full ownership of the enrollment process, making patient recruitment one less challenge for you so you can do what you do best—developing life-saving treatments for the people who urgently need it the most.
From a recent pulmonary trial:
0
Patients enrolled in the U.S. and Europe
0
%
of all submissions enrolled in the study
0
Weeks to complete enrollment campaign
Our​ difference​
Pulmonary trials require reliable patient data from a recruitment partner who has experience in lengthy studies
Pulmonary clinical trials help bring life-saving treatments to high-risk patient populations. Engaging and retaining a diverse pool of participants, often over the course of a wide-ranging longitudinal study, can be challenging.
At 1nHealth, we own the enrollment process from beginning to end. Recruitment doesn’t end when we hand off referrals. It ends at LPI. That allows you and your team to focus on delivering results that push modern medicine forward.
From kick-off to last patient in, 1nHealth builds a reliable source of referred enrollments through high-touch patient engagement
- You need a recruitment partner who understands how every step of the funnel works together to deliver results on time and under budget
- You rely on experts with fine-tuned screening methods so that you're only working with patients who are an ideal study fit
- You demand consistent performance and high-touch patient engagement on lengthy trials that often enroll elderly populations
- You expect quick and efficient site support when trials are enrolling extremely large patient populations globally
Our expertise
COPD
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterized by persistent airflow limitation and chronic inflammation, primarily caused by smoking and environmental exposures.
It affects over 390 million people globally and is a leading cause of morbidity and mortality. Symptoms include dyspnea, chronic cough, and sputum production, significantly impacting quality of life.
COPD is associated with frequent exacerbations and systemic comorbidities, including cardiovascular disease and muscle wasting.
Sleep apnea
Sleep apnea is a common sleep disorder characterized by repeated interruptions in breathing during sleep, leading to oxygen desaturation and fragmented sleep.
The two main types are obstructive sleep apnea (OSA), caused by a collapse of the upper airway, and central sleep apnea, resulting from a failure in the brain’s respiratory control mechanisms.
OSA is associated with cardiovascular disease, hypertension, and metabolic disorders.
Asthma
Asthma is a chronic inflammatory airway disease affecting over 300 million people worldwide, characterized by episodic wheezing, shortness of breath, chest tightness, and coughing.
It involves airway hyperresponsiveness, inflammation, and reversible airflow obstruction, often triggered by allergens, respiratory infections, or environmental factors.
Asthma phenotypes range from mild to severe and include allergic, non-allergic, and late-onset asthma.
Our​ success​
"1nHealth was willing to go above and beyond. They were very responsive, always willing to help, and provided excellent service—ensuring the success of our study!"
Sponsor
Vaping Cessation
Social Anxiety Disorder
Hover to reveal top creative
Healthy Adults Registry
Breast Cancer Chemo Fatigue
Atrial Fibrillation
Hover to reveal top creative
Our experience across other therapeutic areas
Your next trial is thoughtful, complex, and different. Your patient recruitment should be too.
From kick-off to last patient in, 1nHealth builds a reliable source of referred enrollments through proven recruitment programs and high-touch patient engagement.
Click each area to learn more.​
